Organism: Homo sapiens
Gene: 38714_at
Selected probe(set): 205838_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38714_at (205838_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):5.3181963
Number of Samples:5 / 5

Experimental	sickle cell disease study 2 (Globin red.)
	Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclear™-Human kit.
Control	normal blood sample
	Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit including an on-column DNase digestion. Then globin mRNA was depleted using the GLOBINclearTM-Human kit.

Relative Expression (log2-ratio):5.1016912
Number of Samples:5 / 5

Experimental	sickle cell disease study 2 (Pax)
	Whole blood samples of patients with sickle cell disease collected in PAXgene tubes. RNA was extracted using the PAXgene™ Blood RNA System Kit followed by an on-column DNase digestion step.
Control	normal blood sample
	Whole blood samples of healthy volunteers collected in PAXgene tubes. RNA was extracted using the PAXgeneTM Blood RNA System Kit followed by an on-column DNase digestion step.

Relative Expression (log2-ratio):-4.161889
Number of Samples:441 / 74

Experimental	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.7762384
Number of Samples:70 / 74

Experimental	precursor-B-ALL study 1 (t(11q23))
	Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.5822935
Number of Samples:40 / 74

Experimental	AML study 1 (t(8;21)(q22;q22))
	Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(8;21)(q22;q22)).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.421976
Number of Samples:174 / 74

Experimental	T-ALL study 1
	Bone marrow samples of patients with T-ALL.
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.3321524
Number of Samples:121 / 74

Experimental	c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
	Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.329587
Number of Samples:38 / 74

Experimental	AML study 1 (t(11q23))
	Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(11q23)/MLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.3077822
Number of Samples:13 / 74

Experimental	mature B-ALL study 1 (t(8;14))
	Bone marrow samples of patients with mature B-ALL (t(8;14)).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-3.28901
Number of Samples:36 / 74

Experimental	AML study 1 (t(15;17)(q22;q11-12))
	Bone marrow samples of patients with acute promyelocytic leukemia [subtype of acute myeloid leukemia (AML)] with genetic aberration (t(15;17)(q22;q11-12)/PML-RARα and variations).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.